Abstract
AbstractGaps in access to quality essential medicines remain a major impediment to the effective care of children with cancer in low-and middle-income countries (LMICs). The World Health Organization reports that less than 30% of LMICs have consistent availability of childhood cancer medicines, compared to over 95% in high-income countries. Information provided within this policy brief is drawn from a review of the literature and a mixed-methods study published in the Lancet Oncology that analyzed determinants of cancer medicine access for children in Kenya, Tanzania, Uganda, and Rwanda. Three key policy options are presented to guide strategic policy direction and critical health system planning for strengthening access to cancer medicines for children: pooled procurement, evidence-based forecasting, and regional harmonization of regulatory processes. Enhancing regional pooled procurement to address fragmented markets and improve medicine supply, investing in health information systems for improved forecasting and planning of childhood cancer medicine needs, and promoting regulatory harmonization to streamline medicine approval and quality assurance across East Africa are recommended. This policy brief is intended for policymakers, clinicians, and health-system planners involved in the procurement, supply chain management, policy and financing of childhood cancer medicines.
Funder
American Childhood Cancer Association
Canadian Institutes of Health Research
The Hospital for Sick Children
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the cure of all children with cancer through collaborative efforts: Pediatric oncology as a global challenge. J Clin Oncol. 2016;33:3065–73.
2. World Health Organization. WHO Global Initiative for Childhood Cancer: An overview. 2018. Accessed on April 19, 2023 at https://www.who.int/docs/default-source/documents/health-topics/cancer/who-childhood-cancer-overview-booklet.pdf.
3. Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors. Geneva: World Health Organization; (2023). License: CC BY-NC-SA 3.0 IGO.
4. Petricca K, Kambugu J, Githang’a J, Macharia WM, Njuguna F, McLigeyo A, Nyangasi M, Orem J, Kanyamuhunga A, Laiti R, Katabalo D, Schroeder K, Rogo K, Maguire B, Wambui L, Nkurunziza JN, Wong B, Neposlan J, Kilawe L, Gupta S, Denburg AE. Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa. Lancet Oncol. (2023). S1470–2045(23)00072–4. https://doi.org/10.1016/S1470-2045(23)00072-4.
5. World Health Organization. Pooled procurement: WHO guideline on country pharmaceutical pricing policies: a plain language summary. (2021). World Health Organization. https://apps.who.int/iris/handle/10665/341901. License: CC BY-NC-SA 3.0 IGO.